Cancer Gene Therapy Market Analysis
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
The gene therapy market has undergone series of transformation from the initial days of research to current clinical development of drugs for treatment of multiple diseases. The initial studies of gene therapy were conducted mostly on monogenetic diseases, but the focus of the researchers rapidly shifted towards the cancer. The increasing popularity of cancer therapeutics as a major interest for gene therapy applications led to it accounting for a dominant share of more than 60% in the overall number of clinical studies. The reasons for cancer to become a preferred area of application for gene therapy are the significant unmet medical needs in cancer therapy, coupled with the large size of its market. Additionally, the ethical acceptance of gene therapy as a therapeutic solution also contributed to the shift of focus from monogenetic diseases to cancer.
A major part of the cancer gene therapy products for are currently in preclinical and Phase II of clinical trials. There has been marginal success in developing completely curative therapeutic drugs. The gene therapy drugs which have been approved till date are Gendicine & Rexin-G. Gendicine, which is developed by Shenzhen SiBiono Gene Technologies Co., is currently marketed only in China and Rexin-G in Philippines.
Gene therapy offers a large window of opportunities for the treatment of multiple cancers. The therapy has been found to be able to deliver special tumor suppressor genes to an individual, which could prevent the growth of malignant tumors and also reduce the metastatic disease. . The major concentration is being given to the rare tumor types such as pancreatic cancer, and highly prevalent tumor types such as breast cancer and prostate cancer. With the prevalence of cancer rising significantly, the future drug pipelines of the companies are mostly focusing on gene therapy for cancer.
Cancer Gene Therapy Report Highlights & Findings:
The gene therapy market has undergone series of transformation from the initial days of research to current clinical development of drugs for treatment of multiple diseases. The initial studies of gene therapy were conducted mostly on monogenetic diseases, but the focus of the researchers rapidly shifted towards the cancer. The increasing popularity of cancer therapeutics as a major interest for gene therapy applications led to it accounting for a dominant share of more than 60% in the overall number of clinical studies. The reasons for cancer to become a preferred area of application for gene therapy are the significant unmet medical needs in cancer therapy, coupled with the large size of its market. Additionally, the ethical acceptance of gene therapy as a therapeutic solution also contributed to the shift of focus from monogenetic diseases to cancer.
A major part of the cancer gene therapy products for are currently in preclinical and Phase II of clinical trials. There has been marginal success in developing completely curative therapeutic drugs. The gene therapy drugs which have been approved till date are Gendicine & Rexin-G. Gendicine, which is developed by Shenzhen SiBiono Gene Technologies Co., is currently marketed only in China and Rexin-G in Philippines.
Gene therapy offers a large window of opportunities for the treatment of multiple cancers. The therapy has been found to be able to deliver special tumor suppressor genes to an individual, which could prevent the growth of malignant tumors and also reduce the metastatic disease. . The major concentration is being given to the rare tumor types such as pancreatic cancer, and highly prevalent tumor types such as breast cancer and prostate cancer. With the prevalence of cancer rising significantly, the future drug pipelines of the companies are mostly focusing on gene therapy for cancer.
Cancer Gene Therapy Report Highlights & Findings:
- Cancer Gene Therapy Drugs in Pipeline: More Than 60
- Highest Number of Drugs in Preclinical Stage: 37
- Suspended & Discontinued Cancer Gene Therapy Drug Pipeline: 100
- Significance of Oncology Therapeutics in Gene Therapy
- Current Applications of Gene Therapy to Cancer Treatment
- Favorable Parameters for Cancer Gene Therapy
- Issued Involved with Application of Gene Therapy in Cancer Patients
- Regulatory Scenario for Gene Therapy Market
- Cancer Gene Therapy Drug Clinical Trial Insight by Phase, Country & Target Indications
1. INTRODUCTION TO GENE THERAPY
1.1 History of Gene Therapy
1.2 Vectors of Gene Therapy
2. GLOBAL GENE THERAPY MARKET
2.1 Market Overview
2.2 Emerging Trends in Gene Therapy
3. SIGNIFICANCE OF CANCER THERAPEUTICS IN GENE THERAPY
4. CURRENT APPLICATIONS OF GENE THERAPY TO CANCER TREATMENT
4.1 Cancer Treatments Currently Available
4.2 Approaches to Cancer Gene Therapy
4.3 Gene Therapy Used in Cancer Treatment
4.4 Methods of Inserting Genes into Cancer Patients
5. CANCER GENE THERAPY MARKET DYNAMICS
5.1 Favorable Parameters for Cancer Gene Therapy
5.2 Issued Involved with Application of Gene Therapy in Cancer Patients
5.3 Cancer Gene Therapy Clinical Insight
6. REGULATORY SCENARIO FOR GENE THERAPY MARKET
6.1 EU
6.2 US
7. CANCER GENE THERAPY DRUG CLINICAL TRIAL INSIGHT BY PHASE, COUNTRY & TARGET INDICATIONS
7.1 Unknown Phase
7.2 Research
7.3 Preclinical
7.4 Phase I/II
7.5 Phase II
7.6 Phase III
8. MARKETED CANCER GENE THERAPY DRUGS
9. SUSPENDED & DISCONTINUED CANCER GENE THERAPY DRUG PIPELINE
9.1 No Development Reported
9.2 Discontinued
9.3 Suspended
10. COMPETITIVE LANDSCAPE
10.1 Advantagene
10.2 BioCancell
10.3 Celgene
10.4 Cell Genesys
10.5 Epeius Biotechnologies
10.6 GenVec
10.7 Introgen Therapeutics
10.8 MultiVir
10.9 ZIOPHARM Oncology
10.10 Shenzhen SiBiono GeneTech
1.1 History of Gene Therapy
1.2 Vectors of Gene Therapy
2. GLOBAL GENE THERAPY MARKET
2.1 Market Overview
2.2 Emerging Trends in Gene Therapy
3. SIGNIFICANCE OF CANCER THERAPEUTICS IN GENE THERAPY
4. CURRENT APPLICATIONS OF GENE THERAPY TO CANCER TREATMENT
4.1 Cancer Treatments Currently Available
4.2 Approaches to Cancer Gene Therapy
4.3 Gene Therapy Used in Cancer Treatment
4.4 Methods of Inserting Genes into Cancer Patients
5. CANCER GENE THERAPY MARKET DYNAMICS
5.1 Favorable Parameters for Cancer Gene Therapy
5.2 Issued Involved with Application of Gene Therapy in Cancer Patients
5.3 Cancer Gene Therapy Clinical Insight
6. REGULATORY SCENARIO FOR GENE THERAPY MARKET
6.1 EU
6.2 US
7. CANCER GENE THERAPY DRUG CLINICAL TRIAL INSIGHT BY PHASE, COUNTRY & TARGET INDICATIONS
7.1 Unknown Phase
7.2 Research
7.3 Preclinical
7.4 Phase I/II
7.5 Phase II
7.6 Phase III
8. MARKETED CANCER GENE THERAPY DRUGS
9. SUSPENDED & DISCONTINUED CANCER GENE THERAPY DRUG PIPELINE
9.1 No Development Reported
9.2 Discontinued
9.3 Suspended
10. COMPETITIVE LANDSCAPE
10.1 Advantagene
10.2 BioCancell
10.3 Celgene
10.4 Cell Genesys
10.5 Epeius Biotechnologies
10.6 GenVec
10.7 Introgen Therapeutics
10.8 MultiVir
10.9 ZIOPHARM Oncology
10.10 Shenzhen SiBiono GeneTech
LIST OF FIGURES
Figure 3-1: Gene Therapy by Indication
Figure 5-1: Favorable Parameters for Cancer Gene Therapy
Figure 5-2: Cancer Gene Therapy Drug Clinical Pipeline by Phase (%), 2014
Figure 5-3: Cancer Gene Therapy Drug Clinical Pipeline by Phase (Number of Drugs), 2014
Figure 5-4: Suspended Cancer Gene Therapy Drug by Phase (%), 2014
Figure 5-5: Suspended Cancer Gene Therapy Drug by Phase (Number of Drugs), 2014
Figure 5-6: Discontinued Cancer Gene Therapy Drug by Phase (%), 2014
Figure 5-7: Discontinued Cancer Gene Therapy Drug by Phase (Number of Drugs), 2014
Figure 5-8: No Development Reported Cancer Gene Therapy Drug by Phase (%), 2014
Figure 5-9: No Development Reported Cancer Gene Therapy Drug by Phase (Number of Drugs), 2014
Figure 3-1: Gene Therapy by Indication
Figure 5-1: Favorable Parameters for Cancer Gene Therapy
Figure 5-2: Cancer Gene Therapy Drug Clinical Pipeline by Phase (%), 2014
Figure 5-3: Cancer Gene Therapy Drug Clinical Pipeline by Phase (Number of Drugs), 2014
Figure 5-4: Suspended Cancer Gene Therapy Drug by Phase (%), 2014
Figure 5-5: Suspended Cancer Gene Therapy Drug by Phase (Number of Drugs), 2014
Figure 5-6: Discontinued Cancer Gene Therapy Drug by Phase (%), 2014
Figure 5-7: Discontinued Cancer Gene Therapy Drug by Phase (Number of Drugs), 2014
Figure 5-8: No Development Reported Cancer Gene Therapy Drug by Phase (%), 2014
Figure 5-9: No Development Reported Cancer Gene Therapy Drug by Phase (Number of Drugs), 2014
